Prognostic value of cardiac magnetic resonance parameters and biomarkers following myocardial infarction; 10-year follow-up of the Eplerenone Remodelling in Myocardial Infarction without Heart Failure trial

Eur J Heart Fail. 2022 Feb;24(2):393-395. doi: 10.1002/ejhf.2402. Epub 2022 Jan 5.

Authors

Robin A P Weir¹, Suzanne Clements¹, Tracey Steedman², Henry J Dargie³, John J V McMurray⁴

Affiliations

¹ Cardiology Department, University Hospital Hairmyres, Glasgow, UK.
² MRI Department, Queen Elizabeth University Hospital, Glasgow, UK.
³ Cardiology Department, Western Infirmary, Glasgow, UK.
⁴ University of Glasgow BHF Cardiovascular Research Centre, Glasgow, UK.

PMID: 34907636
DOI: 10.1002/ejhf.2402

No abstract available

Publication types

Letter

MeSH terms

Biomarkers
Eplerenone / therapeutic use
Follow-Up Studies
Heart Failure* / diagnosis
Heart Failure* / drug therapy
Humans
Magnetic Resonance Spectroscopy
Mineralocorticoid Receptor Antagonists / therapeutic use
Myocardial Infarction*
Prognosis
Spironolactone / therapeutic use

Substances

Biomarkers
Mineralocorticoid Receptor Antagonists
Spironolactone
Eplerenone